An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors

Author： Murakami H.   Kurata T.   Onozawa Y.   Watanabe J.   Ono A.   Takahashi T.   Yamamoto N.   Fujisaka Y.   Kiyota H.   Hayashi H.   Tanaka K.   Nakagawa K.   Kuroda S.  

Publisher： Springer Publishing Company

ISSN： 0344-5704

Source： Cancer Chemotherapy and Pharmacology, Vol.73, Iss.3, 2014-03, pp. : 623-630

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1–d2–d3) in patients with refractory solid tumors

By Campone M.   Isambert N.   Bourbouloux E.   Maury S.   Monin-Baroille P.   Berille J.   Fumoleau P.  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 5, 2007-04 ,pp. : 689-695

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

By Sausville Edward   LoRusso Patricia   Carducci Michael   Carter Judith   Quinn Mary   Malburg Lisa   Azad Nilofer   Cosgrove David   Knight Richard   Barker Peter   Zabludoff Sonya   Agbo Felix   Oakes Patricia   Senderowicz Adrian  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 539-549

Springer Publishing Company

Access to resources Recommend Favorite

A phase I/II study of carfilzomib 2–10-min infusion in patients with advanced solid tumors

By Papadopoulos Kyriakos   Burris Howard   Gordon Michael   Lee Peter   Sausville Edward   Rosen Peter   Patnaik Amita   Cutler Richard   Wang Zhengping   Lee Susan   Jones Suzanne   Infante Jeffery  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 4, 2013-10 ,pp. : 861-868

Springer Publishing Company

Access to resources Recommend Favorite

Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study

By Mross Klaus   Niemann Bernward   Massing Ulrich   Drevs Joachim   Unger Clemens   Bhamra Rupinder   Swenson Christine  

Cancer Chemotherapy and Pharmacology, Vol. 54, Iss. 6, 2004-12 ,pp. : 514-524

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors

By Masters Gregory   Brockstein Bruce   Mani Sridhar   Ratain Mark  

Medical Oncology, Vol. 20, Iss. 1, 2003-03 ,pp. : 7-12

Humana Press, Inc

Access to resources Recommend Favorite